Victory in the Aloha State

After more than a decade of advocacy by Hawaiian patient and provider advocacy organizations, Hawaii Governor Josh Green signed HB 1864 into law on July 9, 2026. This legislation requires state-regulated health insurers to cover standard fertility preservation services for individuals facing iatrogenic infertility, including cancer patients. The new law will cover procedures such as sperm banking and egg and embryo freezing and go into effect for health plans issued or renewed in Hawaii after December 31, 2026.

Due to Hawaii’s Prepaid Health Care Act of 1974 (PHCA) – the nation’s only state employer health coverage mandate that predates federal ERISA law – coverage will reach a broader percentage of Hawaii’s population compared to other state fertility preservation laws. We estimate that more than 700,000 Hawaiians, approximately half of the state’s population, will now have fertility preservation coverage should they ever need it.

The Alliance for Fertility Preservation would like to thank every patient advocate and organization that has been fighting tirelessly for this coverage since the first Hawaii bill was introduced in 2012. We are especially grateful for the Hawaii Society of Clinical Oncology, ASCO, Fertility Institute of Hawaii, Breast Cancer Hawaii, ACS CAN, Blood Cancer United, Susan G. Komen and all of the patient advocates who bravely shared their stories throughout this long journey.

Fertility Preservation Toolkit

Thank you for your interest in our toolkits. Please read our Terms of Use carefully as we include information that applies to all our toolkits.

All toolkits are publicly available for individual use without licensing or royalty fees. Such use of toolkits is “single use,” meaning solely for the User’s research, clinical, educational, or other application. User’s email may be added to an email distribution list to receive scientific and updated information about the toolkit(s).

We encourage use of our toolkits. User agrees not to adapt, alter, amend, abridge, modify, condense, make derivative works, or translate toolkits without prior written permission from the Provider. User agrees not to sell or incorporate toolkits into materials that could be sold without prior written consent from the Provider. To inquire about permissions, please email info@a4fp.org.


David Stern

David Stern

David Stern has over 30 years of women’s health experience and has devoted the majority of his career to the fertility industry. He has held executive leadership positions and built successful teams while launching numerous products in pharmaceutical and biotech markets world-wide. Currently, David serves as the CEO of Boston IVF, one the largest IVF center networks in the United States with 11 full service IVF centers and over 14 satellite centers nationwide.

David served as CEO of Symbiomix Therapeutics a venture backed biotech company. He led the transition of the company from development stage to commercial launch in the US, prior to its acquisition by Lupin Pharmaceuticals in 2017. He served on the board of California Cryobank and has held executive positions in startup companies in the women’s healthcare market, building commercial teams, developing strategy and expanding scientific partnerships for Celmatix, Ohana and OvaScience.

David was the Senior Vice President and Head of the Global Business Franchise for Fertility at Merck Serono, responsible for the strategic development and growth of the portfolio world-wide. Prior to his global role, he was responsible for the US commercial operations in the Fertility, HIV and Growth Hormone markets. David started his career in women’s health with Organon Pharmaceutics. He has an MBA with a concentration in International Marketing and Management from the F.W. Olin School of Business at Babson College and holds a Bachelors’ degree in Biology from Brandeis University.